21:34 , Jul 26, 2019 |  BC Extra  |  Preclinical News

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

Ribon co-founder reports new mechanism for PARP inhibitors   An University of Texas Southwestern team led by Ribon Therapeutics Inc. (Lexington, Mass.) co-founder W. Lee Kraus reported that PARP inhibitors block ribosome production, and therefore...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Frog studies suggest DDX21 mRNA could help treat Treacher Collins syndrome, a craniofacial disorder caused by mutations in the TCOF1 or Pol I genes. In a Xenopus embryo model of the syndrome, injection...